Please assess the completion status of the following clinical trial:

Trial Title: Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C at screening ≥ 100 mg/dL and ≤ 190 mg/dL~* Fasting triglycerides ≤ 150 mg/dL~* Body mass index (BMI) between 18.0 and 32.0 kg/m\^2~* Framingham cardiac risk score 10% or less~Exclusion Criteria:~* Treatment with a lipid-regulating drug or over the counter supplement in the last 3 months prior to screening~* History of coronary heart disease (CHD) or CHD equivalent~* Uncontrolled hypertension~* Diabetes mellitus

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
- Atorvastatin (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
- Evolocumab (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
- Evolocumab and Atorvastatin (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).